Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Mission Ready Solutions Inc V.MRS.H

Alternate Symbol(s):  MSNVF

Mission Ready Solutions Inc. specializes in providing government contracting solutions through its wholly owned subsidiary, Unifire, Inc. (Unifire) Unifire is a small business and an industry manufacturer and distributor fire, military, emergency, and law enforcement products. It has two business segments in the global defense, security, and first-responder markets: consulting and manufacturer... see more

TSXV:MRS.H - Post Discussion

Mission Ready Solutions Inc > Sona an absolutely poor comparison
View:
Post by ScarletSpider on Feb 18, 2021 7:37am

Sona an absolutely poor comparison

to make. When people raise Sona to this and talk about the uplisting very poor comparison to make. Any pharmaceutical is a very huge risk actually. There are five testing phases with pharma at any time if anything goes wrong in the testing phase it is game over at least to the extent those things get fixed unless it comes to the human testing one where if there are adverse reactions it is done. I held a few in the past and they are extremely risky to gamble with. I dont touch them more because there is animal testing but even so pharma is very risky because at any stage prior to human testing things can go wrong and the share value can get slammed 30 to 60 percent. This is one sector I would pull my investment out when it is there...the faster the better. Now why poor comparison for the obvious reason unless the pharma is ready to roll on shelves as it passed everything successfully there is no product period. This company has either the ppe or sources it always has product so it has been the stock in truth with the least risk and high demand as the ppe has and continues to be essential. As per testing body armor and other materials it can continuously be refined before being supplied and the only risk is if there is a production defect as after thoroughly successfully testing there really should not be any reason for improper function unless as mentioned it just happens to be a production defect which is always possible. As I said very bad comparison to say the least. When people uplist however they should only do so when they have solid foundations to do so like having stable and strong progressive revenue growth flow through via increased sales of products and or service and are looking for stronger capital to raise monies at better values and larger markets if you dont have this or still looking to get product out despite being very close I wouldnt suggest an uplisting...you need stability and proving you can deliver the goods if not you will collapse.
Comment by Abass71 on Feb 18, 2021 8:19am
AGREED ..  you can't compare a legit company like MRS to a small pharma startup. Most of the new businesses in the pharma realm are scams anyway.  They uplist to jack up the price so the insiders can sell and retail bears the brunt after the crash. It's going on right now in the 'shroom business. Then the lawsuits start. MRS is totally legit and worth every penny of a $3-$5 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities